Neurocrine Biosciences (NBIX) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurocrine Biosciences (NBIX)

NBIX 141.80

+0.6%

Dec 31 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: NeuroInvestment who wrote (578)	4/7/2000 2:04:00 AM
From: Miljenko Zuanic	Read Replies (1) of 1834

Rick, Harry, 1. I do not read the some. 16 months ago NBIX/Janssen have back-up compound (from some class) ready. Back-up compound is also covered in DuPont patent and licenses in three way agreement. However, three party agreement also mentioned that NBIX/Janssen are entering new period of the R&D collaboration where new class compounds and lead will be explored. Last news mentioned this new collaboration as source for new compounds, so I am assuming that next candidate will be from new program and (NBIX) library, not from the some class as R121. 2. Based on what I think that R121 is (which class), I did found similar compounds on market or in development, but none with hepatic toxicity. So, it may be derivatization related, and not necessary true for any analogue. 3. NBIX is short on current patents, so it is hard to tell what are this new class compounds. However, NBIX/Janssen were not the only one who failed with first gen. CRF-R1 antagonist because of the toxicity. It may turn out that NBIX proprietary programs/compounds are top-notch, but without further detail I will be cautious about. Miljenko

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next